-
Posted by
Two Blokes Jul 3 -
Filed in
Stock
-
5 views
Initiate Medifast with Strong Buy and $56 PT, citing overlooked operational inflection and coach network momentum driving above-consensus FY26 revenue growth. ASCEND product line and digital engagement tools are key catalysts, improving client retention, coach productivity, and setting the stage for a top line comeback. Valuation is anchored on a conservative 1.3x forward P/S multiple, offering asymmetric risk/reward with tangible execution momentum and significant rerating potential.
